1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Global Sexual Health Partnering 2010-2016: Deal trends, players and financials

Global Sexual Health Partnering 2010 to 2016 provides the full collection of Sexual Health disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Trends in Sexual Health partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Sexual Health partnering agreement structure
Sexual Health partnering contract documents
Top Sexual Health deals by value
Most active Sexual Health dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Sexual Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Sexual Health deals.

The report presents financial deal terms values for Sexual Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Sexual Health dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Sexual Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Sexual Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Sexual Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Sexual Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Sexual Health partnering deals by specific Sexual Health target announced since 2010. The chapter is organized by specific Sexual Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Sexual Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Sexual Health partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Sexual Health technologies and products.


Report scope

Global Sexual Health Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Sexual Health trends and structure of deals entered into by leading companies worldwide.

Global Sexual Health Partnering 2010 to 2016 includes:

Trends in Sexual Health dealmaking in the biopharma industry since 2010
Analysis of Sexual Health deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Sexual Health deal contract documents
Comprehensive access to over 3500 Sexual Health deal records
The leading Sexual Health deals by value since 2010
Most active Sexual Health dealmakers since 2010

The report includes deals for the following indications: Bacterial vaginosis, Candida albicans (Thrush), Contraception, Erectile dysfunction, Sexual dysfunction, Sexually transmitted disease (STI), Chlamydia, Genital warts, Gonorrhea, Herpes, Syphilis, Trichomoniasis, plus other sexual health indications.

In Global Sexual Health Partnering 2010 to 2016, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Sexual Health Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 100 sexual health deals.
Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Table Of Contents

Global Sexual Health Partnering 2010-2016: Deal trends, players and financials
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Sexual Health dealmaking

2.1. Introduction
2.2. Sexual Health partnering over the years
2.3. Sexual Health partnering by deal type
2.4. Sexual Health partnering by industry sector
2.5. Sexual Health partnering by stage of development
2.6. Sexual Health partnering by technology type
2.7. Sexual Health partnering by therapeutic indication

Chapter 3 -Financial deal terms for Sexual Health partnering

3.1. Introduction
3.2. Disclosed financials terms for Sexual Health partnering
3.3. Sexual Health partnering headline values
3.4. Sexual Health deal upfront payments
3.5. Sexual Health deal milestone payments
3.6. Sexual Health royalty rates

Chapter 4 - Leading Sexual Health deals and dealmakers

4.1. Introduction
4.2. Most active in Sexual Health partnering
4.3. List of most active dealmakers in Sexual Health
4.4. Top Sexual Health deals by value

Chapter 5 - Sexual Health contract document directory

5.1. Introduction
5.2. Sexual Health partnering deals where contract document available

Chapter 6 - Sexual Health dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Sexual Health therapeutic target

Appendices

Appendix 1 - Directory of Sexual Health deals by company A-Z 2010 to 2016
Appendix 2 - Directory of Sexual Health deals by deal type 2010 to 2016
Appendix 3 - Directory of Sexual Health deals by stage of development 2010 to 2016
Appendix 4 - Directory of Sexual Health deals by technology type 2010 to 2016
Further reading on dealmaking
Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering


Table of figures

Figure 1: Sexual Health partnering since 2010
Figure 2: Sexual Health partnering by deal type since 2010
Figure 3: Sexual Health partnering by industry sector since 2010
Figure 4: Sexual Health partnering by stage of development since 2010
Figure 5: Sexual Health partnering by technology type since 2010
Figure 6: Sexual Health partnering by indication since 2010
Figure 7: Sexual Health deals with a headline value
Figure 8: Sexual Health deals with upfront payment values
Figure 9: Sexual Health deals with milestone payment
Figure 10: Sexual Health deals with royalty rates
Figure 11: Active Sexual Health dealmaking activity- 2010 to 2016
Figure 12: Top Sexual Health deals by value since 2010

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Ophthalmology Therapeutics - Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the ...

Cardiovascular Surgical Devices: Technologies and Global Markets

Cardiovascular Surgical Devices: Technologies and Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about the trends and developments affecting each type of cardiovascular surgical technology - Analyze trends and opportunities in major regions: North America, Europe, Asia ...

TCR/CAR-T Therapies in Oncology: Analytical Tool

TCR/CAR-T Therapies in Oncology: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.